Salmonella typhi Ty21a bacterial ghost vector augments HIV-1 gp140 DNA vaccine-induced peripheral and mucosal antibody responses via TLR4 pathway.

[1]  J. Berzofsky.  A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. , 2012, Vaccine.

[2]  G. Pantaleo,et al.  Improved NYVAC-Based Vaccine Vectors , 2011, PloS one.

[3]  R. Shattock,et al.  Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice , 2011, European Journal of Immunology.

[4]  J. Brenchley,et al.  Depletion of CD4⁺ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. , 2011, The Journal of clinical investigation.

[5]  B. Walker,et al.  Moving ahead an HIV vaccine: Use both arms to beat HIV , 2011, Nature Medicine.

[6]  C. Sorzano,et al.  A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses , 2011, PloS one.

[7]  K. Yuen,et al.  A method to generate recombinant Salmonella typhi Ty21a strains expressing multiple heterologous genes using an improved recombineering strategy , 2011, Applied Microbiology and Biotechnology.

[8]  D. Mehrotra,et al.  An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). , 2011, The Journal of infectious diseases.

[9]  J. Treanor,et al.  Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. , 2010, Vaccine.

[10]  W. Lubitz,et al.  Bacterial ghosts (BGs)--advanced antigen and drug delivery system. , 2010, Vaccine.

[11]  S. Akira,et al.  Pattern Recognition Receptors and Inflammation , 2010, Cell.

[12]  Ashley T. Haase,et al.  Targeting early infection to prevent HIV-1 mucosal transmission , 2010, Nature.

[13]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[14]  Persephone Borrow,et al.  The immune response during acute HIV-1 infection: clues for vaccine development , 2009, Nature Reviews Immunology.

[15]  Zhiwei Chen,et al.  A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination , 2009, PloS one.

[16]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[17]  J. Schlesinger,et al.  Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells , 2008, Journal of medical virology.

[18]  C. Qiu,et al.  Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses. , 2007, Vaccine.

[19]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[20]  D. Cholujová,et al.  Bacterial Ghosts as Novel Efficient Targeting Vehicles for DNA Delivery to the Human Monocyte-Derived Dendritic Cells , 2005, Journal of immunotherapy.

[21]  Michael G Hudgens,et al.  Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. , 2005, The Journal of infectious diseases.

[22]  W. Lubitz,et al.  DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  W. Lubitz,et al.  Bacterial Ghosts Are an Efficient Delivery System for DNA Vaccines1 , 2004, The Journal of Immunology.

[24]  W. Jacobs,et al.  Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. , 2002, Immunology letters.

[25]  S. Fürst-Ladani,et al.  Activation, stimulation and uptake of bacterial ghosts in antigen presenting cells. , 2000, Journal of biotechnology.

[26]  K. Yuen,et al.  Enhancement by Ampicillin of Antibody Responses Induced by a Protein Antigen and a DNA Vaccine Carried by Live-AttenuatedSalmonella enterica Serovar Typhi , 2000, Clinical Diagnostic Laboratory Immunology.

[27]  W. Lubitz,et al.  Altered temperature induction sensitivity of the lambda pR/cI857 system for controlled gene E expression in Escherichia coli. , 1999, FEMS microbiology letters.

[28]  K. Timmis,et al.  Oral Somatic Transgene Vaccination Using Attenuated S. typhimurium , 1997, Cell.

[29]  J. Clegg,et al.  Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. , 1997, Vaccine.

[30]  F. Heffron,et al.  The lpf fimbrial operon mediates adhesion of Salmonella typhimurium to murine Peyer's patches. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Falkow,et al.  Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches , 1994, The Journal of experimental medicine.

[32]  C. A. Hutchison,et al.  Overlapping genes in bacteriophage φX174 , 1976, Nature.